secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001323885-26-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q1 2026 revenue $141.2M (+14.3%); net income $0.1M; adj. EBITDA $17.1M
-------------------------------------------------------------------------------

- Worldwide revenue $141.2M (+14.3% YoY); U.S. $116.2M (+14.9%), international $25.0M (+11.5%).
- Gross margin 77.4% (+246 bps); income from operations $0.5M vs loss of $6.0M in Q1 2025.
- Net income $0.1M; EPS breakeven at $0.00 (vs net loss $0.14 in Q1 2025).
- Adjusted EBITDA $17.1M, up 95% from $8.8M in Q1 2025.
- No GAAP-to-non-GAAP reconciling items; adjusted EPS also $0.00.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388526000018/0001323885-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388526000018/atrc-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001323885-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer